ClearPoint Neuro Inc.: updates and filings

CLPTNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$7.29

November 19, 2026Market cap $234M

What Ploutos Investor adds for ClearPoint Neuro

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from 2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 27% since Oct 28, 2026, when the 10-Q these figures come from was filed ($10.56 then, $7.71 on Nov 18, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 77 daysAround Feb 4, 2027 · for Q4 2026

last Oct 28, 2026next Feb 4, 2027

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 17, 2026 latest annualOct 28, 2026 latest quarterly
  • Nov 18, 2026Material agreement entered
    Form8-K
  • Nov 18, 2026Shelf registration for future offerings
    FormS-3
  • Nov 3, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 28, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 28, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 4, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 3, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 21, 2026Officer or director change, shareholder vote
    Form8-K
  • May 20, 2026Shares registered for employees
    FormS-8
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 13, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 23, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 20, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 10, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 17, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 17, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Mar 13, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Feb 20, 2026Filing (amendment)
    Form144/A
  • Feb 9, 2026Shares registered for employees
    FormS-8

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 30, 2004. Of its note and share prospectuses (424B, FWP), the newest 40 of 80.

The full analysis

What do ClearPoint Neuro's filings show?

The filings are where every one of ClearPoint Neuro's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.